Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE .Today, we revisit a small biopharma called Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH ) . The company just released Q3 numbers , which were more than solid. In July, I posted an ar ...

Aurinia Pharmaceuticals, Inc. (NASDAQ:AUPH) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Andrea Christopher - Head, Corporate Communications & IR Peter Greenleaf - President, CEO & Director Greg Keenan - Chief Medical Officer Joe Miller - CFO Conference Call Participants Stacy Ku - TD Cowen Maurice Raycroft - Jefferies Olivia Brayer - Cantor Fitzgerald Will Soghikian - Leerink Partners Operator Greetings, and welcome to Aurinia Pharmaceuticals Third Quarter 2024 Earnings ...

Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 400%. A quarter ago, it was expected that this biotechnology company would post earnings of $0.01 per share when it actually produced earnings of $0.02, delivering a surprise of 100%.Over the last four quarters ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________________________________ FORM 10-Q _____________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |------------------------------------------------------------------|------------------ ...

Exhibit 99.1 Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS Growth and AUR200 Development ® • Achieved $67.8 million in total net revenue and $55.5 million in net product revenue for the third quarter of 2024, representing year-over-year growth of 24% and 36%, respectively • Generated $17.0 million in cash flow from operations in the third quarter and had cash, cash equivalents, re ...

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE .Today, we are going to circle back to three small biotech stocks that I have positively highlighted recently that have moved up on good news. All three have what I call the 'Big Mo ...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH ) is a biopharmaceutical company focused on autoimmune diseases. Currently, AUPH’s hit product is LUPKYNIS, which is indicated for managing lupus nephritis [LN]. LN is a complication of systemic lupus erythematosus [SLE]. Thus, LUPKYNIS is an FDA-approved treatment for LN that offersMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in compu ...

When I last covered Aurinia Pharmaceuticals (NASDAQ: AUPH ) (TSX: AUP:CA ) in May, I rated the company a buy, as sales of Lupkynis seemed to have renewed growth. In the past two months, AUPH has; restructured its board, made movesScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure: I/we ha ...

Aurinia Pharmaceuticals, Inc. (NASDAQ:AUPH) Q2 2024 Earnings Conference Call August 1, 2024 8:30 AM ET Company Participants Andrea Christopher - Head, Corporate Communications & IR Peter Greenleaf - President, CEO & Director Greg Keenan - Chief Medical Officer Joe Miller - CFO Conference Call Participants Joseph Schwartz - Leerink Partners Stacy Ku - TD Cowen Ed Arce - H.C. Wainwright & Co. Operator Good day, ladies and gentlemen. Welcome to Aurinia Pharmaceuticals Second Quarter 2024 Earnings Call. [Operat ...

Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 100%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.17 per share when it actually produced a loss of $0.03, delivering a surprise of 82.35%.Over the last four quarters, ...